Liraglutide Weight Loss: Why SLM+ Is Essential Post-Semaglutide Shortage

As of May 2025, the semaglutide and tirzepatide shortages are resolved, prompting many providers to transition patients to liraglutide or dulaglutide for GLP-1 therapy. However, liraglutide weight loss results (5–10% body weight) and dulaglutide outcomes (3–6%) fall short of semaglutide’s 15–20% or tirzepatide’s 20–25%. STAAR LABS’ SLM+ supplement bridges this gap, ensuring your patients achieve semaglutide-level results with liraglutide or dulaglutide. Learn how SLM+ enhances liraglutide weight loss and why it’s a must-have for your practice.

The Weight Loss Gap: Liraglutide and Dulaglutide vs. Semaglutide/Tirzepatide

Semaglutide and tirzepatide have set a high bar for weight loss outcomes:

• Semaglutide (2.4 mg weekly): Patients lost 15–20% of body weight (STEP trials).
• Tirzepatide (15 mg weekly): Up to 20–25% body weight loss (SURPASS trials).
• Liraglutide (3.0 mg daily): Only 5–10% body weight loss, or 10–20 lbs.
• Dulaglutide (4.5 mg weekly): Just 3–6% body weight loss, often 5–15 lbs.

Patients switching to liraglutide or dulaglutide may see their weight loss stall, risking frustration and non-adherence. As a provider, you need a solution to maintain the transformative results they expect.

SLM+: The Key to Enhanced Liraglutide and Dulaglutide Weight Loss

STAAR LABS’ SLM+ combines perfectly with  liraglutide or dulaglutide to maximize weight loss outcomes. SLM+ is the critical component that makes liraglutide weight loss comparable to semaglutide:

• Boosts GLP-1 Levels: Increases endogenous GLP-1 production by up to 25%, enhancing satiety.
• Accelerates Fat Burning: Mimics GIP, turbocharging glucose metabolism.
• Improves Metabolic Efficiency: Enhances insulin sensitivity via GLUT-4 translocation.
• Reduces Side Effects: Minimizes nausea, ensuring patients stay on track.

Pilot data shows patients on SLM+ lose up to 46 lbs—results that rival semaglutide and tirzepatide. Without SLM+, your patients may struggle to achieve even half that impact.

What to Expect During the Transition to Liraglutide or Dulaglutide

• Adjustment Period: Patients may experience nausea or GI discomfort in the first 4–6 weeks, especially with dulaglutide (up to 30% incidence). SLM+ reduces these side effects.
• Slower Weight Loss: Without SLM+, patients may lose only 3–10% of body weight, compared to 20–25% with their previous therapy.
• Patient Frustration: Reduced efficacy can lead to dissatisfaction and non-adherence.

Why SLM+ Is Essential for Your Practice

• Achieve Semaglutide-Level Results: Up to 46 lbs weight loss with SLM+ when used with GLP-1 therapy, compared to 10–20 lbs without.
• Boost Patient Satisfaction: Noticeable results within 8–12 weeks, maintaining motivation.
• Reduce Side Effects: SLM+ minimizes nausea, improving adherence.

Take Action: Elevate Your Practice with SLM+

Don’t let the shortage resolution compromise your patients’ results. Integrate SLM+ into your liraglutide and dulaglutide protocols to deliver transformative outcomes. Contact STAAR LABS at info@staarlabs.com to schedule a demo and learn how SLM+ can elevate your practice.

🛡 Disclaimers

Medical Disclaimer:

This blog is for informational purposes only and is not intended as medical advice. Always consult your healthcare provider before making any changes to your medications, supplements, or health regimen. Individual results may vary.

Supplement Disclaimer:

Statements regarding dietary supplements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

Research & Innovation Disclosure:

STAAR LABS conducts protocol development in collaboration with licensed providers and pharmacies. Our research focuses on combining nutraceutical and pharmaceutical interventions to enhance metabolic outcomes. Weight loss projections involving SLM+ are based on early observational feedback and theoretical mechanisms, not yet published in peer-reviewed clinical trials.